logo/base Created with Sketch.
Contact us

FibroScan® Mini+ 430

The mobile non-invasive solution for liver disease management.

Powered by LSM by VCTE® and CAP for liver disease assessment.

chevron chevron

Seamlessly adaptable to all settings

FibroScan® Mini+ 430 is a point-of-care mobile solution for hospital and office-based settings

Mobile

Light and easy to handle with airplane-compatible transport suitcase. Battery-powered device

Innovative design

Winner of the Red Dot Design Award 2017

All patient morphologies

Can be used with all probes S+, M+ and XL+

Renowned & Endorsement

Supported by 6,270+ peer reviewed publications and 250+ international guidelines

Patented and Validated

LSM by VCTE® is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness with 5,540+ international peer-reviewed publications.1

CAP is unique patented and validated for liver steatosis assessment2,3 with 2,125+ international peer-reviewed publications.

Learn more
FibroScan® Mini+ 430

Guided VCTE®: The next generation VCTE® technology

The new Guided VCTE® technology offers intuitive features for faster examinations and simplified scanning.

Learn more about Guided VCTE More information about FibroScan exams

FibroScan® Mini+ 430 comes with a dedicated support

From installation, to training and local support, we provide you with the highest quality of services.

Learn more

Extend FibroScan® use

Beyond FibroScan®, Echosens offers complementary solutions designed to extend liver disease assessment, support clinical decision-making and optimize patient follow-up across different care pathways.

  • FibroScan® Gateway

    FibroScan® Gateway

    Optimize clinical workflows with real-time secure data transmission

    chevron
  • FibroScan® Guided VCTE

    Guided VCTE®

    Seamless liver health assessment for all

    chevron
  • FibroScan® probes

    VCTE® probe

    Optimize measurement accuracy on all patients of varying size

    chevron
  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron

What our users say

The ability FibroScan gives to painlessly and quickly locate a liver health risk to a person, which also is one of the world’s biggest silent killers is a no brainer. I have yet to have any person tell me they didn’t want to know, in fact the complete opposite almost everyone alters something in their lives to improve their own and families liver health. 

Louise Campbell

Founder and Medical Director Tawazun Health

Guided VCTE technology has significantly improved the operator’s confidence that the probe is in the right place over the liver, excluding either lung or rib artifact. This will also enhance reliability when performing sequential scans on the same patient.

Dr. Martin Grajower

MD, FACP, FACE | Endocrinologist, Clinical Professor of Medicine | Albert Einstein College of Medicine

In the mobile screening program, the FibroScan is both a screening tool and a diagnostic referral tool. It allows us to open up discussion on alcohol and viral hepatitis issues, but also to screen for hepatopathies and organize appropriate follow-up. This tool gives us great autonomy and supports our Risk Reduction approach.

Johann Volant

HIV-Hepatitis Coordinator Association Gaïa-Paris

Read all testimonials chevron

Request a demo!

Interested in FibroScan®?

Contact us

1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.

2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.

3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

The FibroScan® 430 Mini+ is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE® ) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP)* at 3.5 MHz. FibroScan® liver stiffness measurements (LSM) by VCTE® may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan® CAP measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis.  FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. * CAP refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP on S+ probe is only available with SmartExam capability.

chevron User Guides FibroScan Mini+ 430